Abstract: The invention relates to a process for in vitro diagnosis of an infection by human cytomegaloviruses. The process consists of contacting cells, possibly carrying the infection, with a monoclonal antibody reacting with a polypeptide of molecular weight 68,000, induced by human cytomegalovirus and which possesses a protein-kinase activity. The detection of the reaction is preferably carried out by immunofluorescence.
Type:
Grant
Filed:
August 5, 2002
Date of Patent:
September 27, 2005
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique, Institut National de la Sante de la Recherche Medicale
Inventors:
Florian Horaud, Susan Michelson, Octavian Barzu, Andre Boue, Claire Amadei
Abstract: The present invention relates, in part, to a purified polyclonal or monoclonal antibody which recognizes an epitope of a protein of 48,000 dalton, where the protein recognizes is a surface protein of a merozoite of Plasmodium falciparum which has a peptide of SEQ ID NO:1 or a sequence wherein SEQ ID NO:1 has been modified by insertion, deletion or substitution and the sequence inhibits the binding of inonoclonal antibody 245 to Plasmodium merozoites, as well as fragments of the antibody; the present invention relates to composition and kits containing the same, as well as methods of using the same;
Type:
Grant
Filed:
September 11, 2002
Date of Patent:
September 27, 2005
Assignee:
Institut Pasteur
Inventors:
Pierre Druilhe, Hasnaq Bouharoun-Tayoun, Claude Oeuvray
Abstract: The present invention relates to peptide sequences enabling mycobacteria to adhere to host cells (e.g., epithelial cells). More particularly, the invention relates to a mycobacterial heparin-binding haemagglutinin type antigen from M. bovis ECG or M. tuberculosis. The invention also relates to a recombinant peptide sequence enabling mycobacteria to adhere to host cells. The polypeptides can be used to prepare vaccines against mycobacterial infections and for serological diagnosis of mycobacterial infections.
Type:
Grant
Filed:
November 17, 1998
Date of Patent:
September 27, 2005
Assignees:
Institut National de la Sante et de la Recherche Medicale, Institut Pasteur de Lille
Abstract: The present invention pertains to polynucleotides derived from staphylococcal genes encoding resistance to streptogramin A or to streptogramin B and chemically related compounds. This invention also relates to the use of the polynucleotides as oligonucleotide primers or probes for detecting Staphylococcal strains that are resistant to streptogramin A or to streptogramin B and related compounds in a biological sample. In another embodiment, the present invention is directed to the full length coding sequences of the staphylococcal genes encoding for resistance to streptogramin A or to streptogramin B from Staphylococcus and to the polypeptides expressed by these full length coding sequences. Further, this invention relates to the use of the expressed polypeptides to produce specific monoclonal or polyclonal antibodies that serve as detection means in order to characterize any staphylococcal strain carrying genes encoding resistance to streptogramin A or to streptogramin B.
Abstract: This invention relates to vectors, bacterial strains, and methods for the cloning and expression of a polypeptide having larvicidal activity. In particular, the invention relates to vectors, bacterial strains and methods for the cloning and expression of the N-terminal region of a polypeptide toxic against the larvae of Lepidoptera of the Noctuidae family, preferably against S. littoralis.
Type:
Grant
Filed:
August 1, 2001
Date of Patent:
September 13, 2005
Assignees:
Institut Pasteur, Institute National de la Recherche Agronomic
Inventors:
Vincent Sanchis, Didier Lereclus, Ghislaine Menou, Marguerite-Marie Lecadet, Daniel Martouret, Raymond Dedonder
Abstract: The present invention provides a method for obtaining thermostable enzymes. The present invention also provides variants of DNA polymerase I from Thermus aquaticus. The present invention further provides methods of identifying mutant DNA polymerases having enhanced catalytic activity. The present invention also provides polynucleotides, expression systems, and host cells encoding the mutant DNA polymerases. Still further, the present invention provides a method to carry out reverse transcriptase-polymerase chain reaction (RT-PCR) and kits to facilitate the same.
Abstract: A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).
Type:
Grant
Filed:
December 2, 2002
Date of Patent:
August 30, 2005
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Inventors:
Valérie Baubet, Hervé Le Mouellic, Philippe Brulet
Abstract: The present invention pertains to polynucleotides derived from staphylococcal genes encoding resistance to streptogramin A or to streptogramin B and chemically related compounds. This invention also relates to the use of the polynucleotides as oligonucleotide primers or probes for detecting Staphylococcal strains that are resistant to streptogramin A or to streptogramin B and related compounds in a biological sample. In another embodiment, the present invention is directed to the full length coding sequences of the staphylococcal genes encoding for resistance to streptogramin A or to streptogramin B from Staphylococcus and to the polypeptide expressed by these full length coding sequences. Further, this invention relates to the use of the expressed polypeptides to produce specific monoclonal or polyclonal antibodies that serve as detection means in order to characterize any staphylococcal strain carrying genes encoding resistance to streptogramin A or to streptogramin B.
Abstract: The present invention provides antibodies that specifically bind RSP-2 proteins which are involved in the cytoadhesion of P. falciparum during ring-stage infection of erythrocytes as well as methods of using these antibodies.
Type:
Application
Filed:
April 1, 2005
Publication date:
August 4, 2005
Applicants:
INSTITUT PASTEUR, Centre National De La Recherche Scient.
Inventors:
Juerg Gysin, Arthur Scherf, Catherine Lepolard
Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.
Type:
Application
Filed:
October 4, 2004
Publication date:
July 28, 2005
Applicants:
INSTITUT PASTEUR, KIMRON VETERINARY INSTITUTE
Inventors:
Philippe Despres, Vincent Deubel, Jean-Louis Guenet, Marie-Therese Drouet, Mertyn Malkinson, Caroline Banet, Marie-Pascale Frenkiel, Marie-Pierre Courageot, Fasseli Coulibaly, Adeline Catteau, Marie Flamand, Patrick Weber, Pierre-Emmanuel Ceccaldi
Abstract: The invention relates to peptides having the formula (I): X-His-Asn-Pro-Y wherein X is a rest Gln or pyro-Glu. Y is a group OH or a rest of basic aminoacid.
Abstract: The invention relates to a composition of polypeptides, characterized in that it contains at least one protein or part of a protein selected from the sequences of amino acids identified in the list of the sequences as SEQ ID NO 1 (VanH), SEQ ID NO 2 (VanA).
Type:
Grant
Filed:
July 20, 1999
Date of Patent:
July 12, 2005
Assignee:
Institut Pasteur
Inventors:
Michel Arthur, Sylvie Dukta-Malen, Catherine Molinas, Patrice Courvalin
Abstract: The present invention relates to peptides and polypeptide derived from the submaxillary gland of the rat. In particular, the present invention discloses a purified peptide of formuls: X-His-Asn-Pro-Y in which X represents a Gln or Pro-Glu residue and Y represents an OH group or residue of a basic amino acid. The present invention also relates to corresponding polyclonal and monoclonal antibodies as well as corresponding hybridomas. The products of the present invention are useful for therapeutic, diagnosis and detection purposes.
Type:
Grant
Filed:
August 31, 1999
Date of Patent:
July 12, 2005
Assignee:
Institute Pasteur
Inventors:
Isabelle Rosinski-Chupin, Diana Tronik, François Rougeon, Nabil Seidah
Abstract: The present invention is directed to a method for selecting a prey polypeptide that is able to interact with a bait polypeptide of interest, to a prey polynucleotide encoding the prey polypeptide as well as to the prey polypeptide itself. The invention also concerns plasmids used for performing the method of the invention as well as prokaryotic or eukaryotic recombinant host organisms containing such plasmids and also a collection of said recombinant host organisms consisting in a DNA library, such as a collection of recombinant haploid Saccharomyces cerevisiae. Finally, the invention is also directed to a technical medium containing the whole information concerning the interactions between metabolically related bait and prey polypeptides and/or polynucleotides coding for bait and prey polypeptides.
Type:
Grant
Filed:
October 25, 2002
Date of Patent:
July 5, 2005
Assignee:
Institut Pasteur
Inventors:
Pierre Legrain, Micheline Fromont, Jean-Christophe Rain
Abstract: A gene encoding an acetyltransferase inactivating streptogramin A was isolated from an Enterococcus faecium strain and sequenced. The gene, designated vatE, encodes a 23.775 kDa protein exhibiting 48.5 to 59.9% amino acid identity with four other enzymes with the same activity, Vat, VatB, VatC and SatA.
Type:
Grant
Filed:
July 28, 2000
Date of Patent:
June 14, 2005
Assignee:
Institut Pasteur
Inventors:
Julien Haroche, Jeanine Allignet, Nevine El Solh
Abstract: The present application relates to nucleotide sequences which regulate the biosynthesis of the flagella proteins Helicobacter pylori, to the proteins encoded by these sequences and to a aflagellate bacterial strains. The invention also relates to the use of these means for detecting an infection due to H.pylori or for protecting against such an infection.
Type:
Grant
Filed:
September 10, 2002
Date of Patent:
May 31, 2005
Assignees:
Institut Pasteur, Institute National de la Sante et de la Recherche Medicale
Abstract: The invention relates to a composition of polypeptides, characterized in that it contains at least one protein or part of a protein selected from the sequences of amino acids identified in the list of the sequences as SEQ ID NO 1 (VanH), SEQ ID NO 2 (VanA), SEQ ID NO 3 (VanX) or SEQ ID NO 19 (VanC), or any protein or part of a protein recognized by the antibodies directed against VanH, VanA, VanX or VanC, or any protein or part of a protein encoded in a sequence hybridizing with one of the nucleotide sequences identified in the list of the sequences as SEQ ID NO 8, SEQ ID NO 9 or SEQ ID NO 10 or with one of the following sequences V1 or V2 under stringent or only slightly stringent conditions: V1: GGX GAA GAT GGX TCX TTX CAA GGX ??G ??C AG C ??G A V2: AAT ACX ATX CCX GGX TTT AC ??C T ??C C The invention also relates to the nucleotide sequences coding for these polypeptides as well as their utilization for the diagnosis of resistance to the glycopeptides.
Type:
Application
Filed:
September 30, 2004
Publication date:
May 26, 2005
Applicant:
INSTITUT PASTEUR
Inventors:
Michel Arthur, Sylvie Dukta-Malen, Catherine Molinas, Patrice Courvalin
Abstract: This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments of the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.
Type:
Grant
Filed:
February 25, 1994
Date of Patent:
May 17, 2005
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Inventors:
Marc Alizon, Pierre Sonigo, Cole Stewart, Oliver Danos, Simon Wain-Hobson
Abstract: The present invention relates to nine residue peptides (M32-40) from flavivirus M ectodomain able to modulate specifically the apoptotic activity of diverse flavivirus, to pharmaceutical composition comprising the same and their use for the treatment and/or the prevention of flavivirus-linked infections and cancers.